Quotient Sciences' CEO, Mark Egerton, featured in 2022 edition of U.S. Pharma and Biopharma Report
In this interview, Mark Egerton, CEO of Quotient Sciences, states that "Quotient Sciences wants to support our customers with their molecules earlier in the development process, from the point at which the drug candidate molecule is selected from the discovery program."
Quotient Sciences SME comments on solubility & bioavailability challenges in Drug Development & Delivery feature article
John McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.
Mark Egerton featured in Pharma's Almanac roundtable article: What’s the key to being a leader in the industry?
In this roundtable with Pharma's Almanac, Mark Egerton, CEO of Quotient Sciences, answers the Question 'What’s the key to being a leader in the industry?
International Journal of Pharmaceutics - Practical and operational considerations related to pediatric oral drug formulation: An industry survey
Quotient Sciences' Dr Shriram Pathak, Senior Research Fellow, has contributed to a publication in the International Journal of Pharmaceutics. The title of the publication is 'Practical and operational considerations related to paediatric oral drug formulation: An industry survey'
Vanessa Zann and Chris Roe: Q&A with Pharmaceutical Technology on Successfully Accelerating Formulation Strategies
Accelerated formulation strategies can aid with cost and time-efficiencies in drug development. However, there are key challenges of which developers must be aware to ensure success. To discuss the primary hurdles to accelerated formulation strategies and best practices for developers.
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant Topline results expected Q3 2022